Stock Track | Scholar Rock Soars 6.35% in Pre-market on $550M Debt Facility, FDA Progress and Better-Than-Expected Q4 Results

Stock Track

Mar 03

Scholar Rock Holding Corp's stock soared 6.35% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant business updates.

The biopharmaceutical company reported a Q4 net loss of $0.88 per share, which was slightly better than the FactSet consensus estimate of a $0.89 loss. More importantly, the company announced it secured up to $550 million in non-dilutive capital to support the commercialization of its lead candidate, apitegromab, and advance its pipeline.

Investors reacted positively to the constructive regulatory update, as the company stated its meeting with the FDA regarding the Catalent Indiana facility required no additional corrective actions, supporting its plans to resubmit the Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy. The company anticipates U.S. and European launches of the drug in 2026, pending regulatory approvals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152199204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152199204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152199204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152199204","market":"hk","top_or_hot":-1,"title":"Stock Track | Scholar Rock Soars 6.35% in Pre-market on $550M Debt Facility, FDA Progress and Better-Than-Expected Q4 Results","media":"Stock Track","content":"<p>Scholar Rock Holding Corp's stock soared 6.35% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant business updates.</p><p>The biopharmaceutical company reported a Q4 net loss of $0.88 per share, which was slightly better than the FactSet consensus estimate of a $0.89 loss. More importantly, the company announced it secured up to $550 million in non-dilutive capital to support the commercialization of its lead candidate, apitegromab, and advance its pipeline.</p><p>Investors reacted positively to the constructive regulatory update, as the company stated its meeting with the FDA regarding the Catalent Indiana facility required no additional corrective actions, supporting its plans to resubmit the Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy. The company anticipates U.S. and European launches of the drug in 2026, pending regulatory approvals.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Scholar Rock Soars 6.35% in Pre-market on $550M Debt Facility, FDA Progress and Better-Than-Expected Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Scholar Rock Soars 6.35% in Pre-market on $550M Debt Facility, FDA Progress and Better-Than-Expected Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Scholar Rock Holding Corp's stock soared 6.35% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant business updates.</p><p>The biopharmaceutical company reported a Q4 net loss of $0.88 per share, which was slightly better than the FactSet consensus estimate of a $0.89 loss. More importantly, the company announced it secured up to $550 million in non-dilutive capital to support the commercialization of its lead candidate, apitegromab, and advance its pipeline.</p><p>Investors reacted positively to the constructive regulatory update, as the company stated its meeting with the FDA regarding the Catalent Indiana facility required no additional corrective actions, supporting its plans to resubmit the Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy. The company anticipates U.S. and European launches of the drug in 2026, pending regulatory approvals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRRK","symbol_name":"Scholar Rock Holding Corp","start_time":0,"source_url":"","article_id":"1152199204","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152199204","pubTimestamp":1772548465,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Scholar Rock Holding Corp's stock soared 6.35% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRRK":"Scholar Rock Holding Corp"},"translate_title":"个股追踪|受5.5亿美元债务融资、FDA进展和好于预期的第四季度业绩影响，Scholar Rock盘前飙升6.35%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":1},"content_text":"Scholar Rock Holding Corp's stock soared 6.35% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant business updates.The biopharmaceutical company reported a Q4 net loss of $0.88 per share, which was slightly better than the FactSet consensus estimate of a $0.89 loss. More importantly, the company announced it secured up to $550 million in non-dilutive capital to support the commercialization of its lead candidate, apitegromab, and advance its pipeline.Investors reacted positively to the constructive regulatory update, as the company stated its meeting with the FDA regarding the Catalent Indiana facility required no additional corrective actions, supporting its plans to resubmit the Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy. The company anticipates U.S. and European launches of the drug in 2026, pending regulatory approvals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}